Trial Profile
An Open-Label, Drug-Drug Interaction Study to Examine the Effects of Dupilumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Patients With Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary) ; Caffeine; Metoprolol; Midazolam; Omeprazole; Warfarin
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Regeneron Pharmaceuticals
- 02 Mar 2018 Results published in the Clinical Pharmacology and Therapeutics
- 18 Aug 2016 Status changed from recruiting to completed.
- 11 Jan 2016 New trial record